MOUNTAIN VIEW, Calif., Feb. 28, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 29, 2012.
CEO William M. Moore said, "We have implemented a number of changes to the organization flattening the management structure and making the focus more customer-centric and market driven with an eye to profitability. We are now investing in products that our customers want, that can be delivered to the market in a reasonable amount of time and that are aligned with growing clinical trends in ophthalmology. And we are making these changes in the framework of fiscal controls and a focus on generating cash and enhancing shareholder value."
Moore continued, "Going forward, we will look to grow and increase profitability, we will be opportunistic in acquiring or partnering with ophthalmic companies that have developed excellent technologies and we will continue to deploy cash from our strong balance sheet and profitable operations to directly benefit our shareholders through our share buyback program. For the last two years we had committed up to $4.0 million to our stock repurchase program which ended this February. Today, the Board approved a new one year $3.0 million stock repurchase program that replaces our prior two year $4.0 million program."
The preceding commentary relates to the results of the Company's continuing ophthalmology business. In February 2012, the Company sold its aesthetics laser business and the financial statements reflect the results of its aesthetics laser business as discontinued operations.
Fourth Quarter Business Highlights
Conference Call IRIDEX management will conduct a conference call later today, Thursday, February 28, 2013 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (866) 225-8754 (U.S.) or (480) 629-9818 (International) and quoting Conference ID 4603021, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, February 28, 2013 through Thursday, March 7, 2013 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4603021. In addition, later today an archived version of the webcast will be available on the Company's website at www.iridex.com.
About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at http://www.iridex.com/.
Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of and trends in the markets in which the Company operates, the success of the Company's development, marketing and sales efforts, MicroPulse laser therapy, the Company's growth strategy, the Company's acquisition strategy, sales revenue growth, operational plans, profitability, the Company's projected fiscal 2013 financial results and the Company's share repurchase program. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012, June 30, 2012 and September 29, 2012 which were filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
IRIDEX CorporationCondensed Consolidated Statements of Operations(In thousands, except per share data)(unaudited)Three Months EndedTwelve Months EndedDecember 29,December 31,December 29,December 31,2012201120122011Total revenues
33,159Cost of revenues
4,3384,27816,34616,290Operating expenses:Research and development
1,0911,1664,3853,913Sales and marketing
2,0342,1477,8957,458General and administrative
9081,0664,9264,259Legal settlement, net of expenses
-(1,274)-(1,274)Total operating expenses
4,0333,10517,20614,356Income (loss) from operations
--800800Other expense, net
(18)(250)(210)(296)Income (loss) from continuing operations before income taxes
287923(270)2,438Provision for (benefit from) income taxes
34122(100)297Income (loss) from continuing operations
253801(170)2,141Income (loss) from discontinued operations, net of tax
149(15)(264)469(Loss) gain on sale of discontinued operations, net of tax
(160)-1,872-(Loss) income from discontinued operations, net of tax
2,610Net (loss) income per share: Basic: Continuing operations
$0.03$0.09($0.02)$0.24 Discontinued operations
($0.00)($0.00)$0.18$0.05$0.03$0.09$0.16$0.29 Diluted: Continuing operations
$0.03$0.08($0.02)$0.21 Discontinued operations
($0.01)($0.00)$0.18$0.05$0.02$0.08$0.16$0.26Weighted average shares used in computing net income per share Basic
IRIDEX CorporationCondensed Consolidated Balance Sheets(In thousands)(unaudited)December 29,December 31,20122011AssetsCurrent Assets:Cash and cash equivalents
,789Accounts receivable, net
8,0356,659Prepaids and other current assets
1,129464Current assets of discontinued operations
5106,043Total current assets
27,05529,506Property and equipment, net
483325Other long-term assets
287199Other intangible assets, net
533533Non-current assets of discontinued operations
$ 28,912$ 32,149Liabilities and Stockholders' EquityCurrent Liabilities:Accounts payable
1,0041,014 Current liabilities of discontinued operations
-2,663Total current liabilities
6,3678,913Long Term Liabilities:Other long-term liabilities
7,0079,723Stockholders' Equity:Convertible preferred stock
9492Additional paid-in capital
38,95842,032Accumulated other comprehensive loss
-(35)Treasury stock, at cost
(17,152)(18,590)Total stockholders' equity
21,90522,426Total liabilities and stockholders' equity
$ 28,912$ 32,149
|SOURCE IRIDEX Corporation|
Copyright©2012 PR Newswire.
All rights reserved